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Protocol
AbstrACt
Introduction Persons with type 1 diabetes require intensive 
insulin therapy to achieve glycaemic control, but side effects, 
including hypoglycaemia and weight gain, may reduce 
treatment compliance. We hypothesise that add-on treatment 
of the short-acting glucagon-like peptide-1 receptor agonist, 
exenatide, to insulin therapy in persons with type 1 diabetes 
will reduce insulin requirements, glycaemic excursions and 
body weight and improve glycaemic control without increasing 
the risk of hypoglycaemia. The present article describes a 
protocol developed to test this hypothesis.
Methods and analysis One-hundred adult persons with 
type 1 diabetes for more than 1 year, insufficient glycaemic 
control (glycated haemoglobin A1c (HbA1c) between 58 
and 86 mmol/mol) and body mass index >22.0 kg/m2 will 
be randomised to either exenatide 10 µg three times per 
day (at meal times) or placebo as add-on therapy to regular 
basal–bolus insulin treatment for 26 weeks. Primary endpoint 
is change in HbA1c between the two groups at end of 
treatment. Secondary endpoints include change in glycaemic 
excursions (assessed by continuous glucose monitoring); 
insulin dose; hypoglycaemic and adverse events; body weight, 
lean body and fat mass; dietary patterns; quality of life and 
treatment satisfaction; cardiovascular-disease risk profile; 
metabolomics; and arginine-tested plasma glucose, glucagon 
and C-peptide levels.
Ethics and dissemination The study is approved by the 
Danish Medicines Agency, the Regional Scientific Ethics 
Committee of the Capital Region of Denmark and the Data 
Protection Agency. The study will be carried out under the 
surveillance and guidance of the good clinical practice 
(GCP) unit at Copenhagen University Hospital Bispebjerg in 
accordance with the ICH-GCP guidelines and the Helsinki 
Declaration. Positive, negative as well as inconclusive 
results will be sought disseminated at scientific meetings 
and in international peer-reviewed scientific journals.
trial registration number NCT03017352.
IntroduCtIon 
background and rationale
Type 1 diabetes is a global disease affecting 
millions of people with increasing incidence.1 2 
The majority of persons with type 1 diabetes 
do not achieve glycaemic control, and up 
to 50% are overweight or obese with a body 
mass index >25 kg/m2.3–6 Intensive insulin 
treatment is necessary to ensure glycaemic 
control that delays the onset and slows the 
progression of microvascular complications, 
that is, diabetic retinopathy, neuropathy, 
nephropathy and macrovascular disease.7–9 
Failure to achieve glycaemic control may 
occur due to side effects of intensive insulin 
treatment, that is, weight gain and hypogly-
caemia.10 11 Both weight gain and hypogly-
caemia have been shown to reduce treatment 
compliance. Severe hypoglycaemia is associ-
ated with serious physiological and psycho-
logical comorbidity and even death.11 Milder 
hypoglycaemic episodes lead to fear of future 
episodes, and unwanted weight gain leads 
to reduced insulin doses.12 13 Overweight 
itself is unwanted among persons with type 1 
diabetes and associated with its own problems, 
strengths and limitations of this study
 ► First randomised, double-blinded, placebo-con-
trolled trial to investigate a short-acting gluca-
gon-like peptide-1 receptor agonist as add-on 
therapy in type 1 diabetes.
 ► This study will include normal to overweight persons 
with insufficient glycaemic control, who represent 
a large proportion of persons with type 1 diabetes 
worldwide.
 ► The study is powered to draw conclusions on gly-
caemic control (as assessed by glycated haemo-
globin), glycaemic variability and time spent in 
near normoglycaemia.
 ► The study may not be sufficiently powered to draw 
firm conclusions on all secondary endpoints.
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for example, hypertension, cancer and increased cardio-
vascular disease risk.14 
To improve treatment of type 1 diabetes, these prob-
lems must always be considered and addressed. Add-on 
therapy of non-insulin drugs developed for type 2 diabetes 
has recently gained increasing interest within type-1-dia-
betes research.15 The incretin hormone, glucagon-like 
peptide-1 (GLP-1), regulates glucose metabolism through 
GLP-1 receptor-induced pancreatic and extrapancreatic 
effects, for example, increased glucose-dependent insulin 
secretion, lowered postprandial glucagon secretion and 
reduced rate of gastric emptying.16 Furthermore, GLP-1 
promotes satiety and thereby facilitates body weight loss. 
Several GLP-1 receptor agonists (GLP-1RAs) are used 
successfully in the treatment of type 2 diabetes—including 
insulin-treated persons with type 2 diabetes.17 Based on 
their pharmacokinetic profiles, the GLP-1RAs can be 
divided into short-acting or long-acting compounds with 
important between-class differences.
In type 2 diabetes, long-acting compounds exert 
continuous insulinotropic and glucagonostatic effects. 
Therefore, they have a greater—and sustained—effect 
on fasting plasma glucose compared with the short-acting 
GLP-1RAs. Lowering of fasting plasma glucose is pivotal 
in insulin-treated type 2 diabetes, and long-acting-com-
pound treatment therefore generally translates into better 
glycaemic control compared with short-acting GLP-1RAs. 
In contrast, treatment with short-acting GLP-1RAs exerts 
potent and sustained slowdown of gastric emptying with 
an effective lowering of postprandial plasma glucose 
excursions, an effect lost with long-acting GLP-1RAs 
due to tachyphylaxis.17 Thus, persons with adequately 
controlled fasting plasma glucose that are in need for 
postprandial glucose lowering to achieve glycaemic 
control will most likely benefit more from a short-acting 
GLP-1RA compared with a long-acting GLP-1RA.18 In 
contrast to the different, glucose-lowering effects of the 
different GLP-1RAs, the body weight-reducing effects of 
GLP-1RAs seem independent of their pharmacokinetic 
profile.17
GLP-1RAs provide a valuable treatment concept for 
persons with type 2 diabetes. Their insulin-independent 
effects, that is, glucose-dependent glucagon suppres-
sion (occurring only at plasma glucose concentrations 
above 4–5 mmol/L), appetite reduction and decelera-
tion of gastric emptying, make them interesting from a 
type-1-diabetes management perspective. The long-acting 
GLP-1RA, liraglutide, was previously examined in several 
randomised, double-blinded, placebo-controlled trials 
as add-on treatment in persons with type 1 diabetes. 
These studies indicated substantial reductions in body 
weight and total exogenous insulin dose and, in general, 
moderate improvements in glycaemic control, but at the 
expense of increased incidences of symptomatic hypo-
glycaemia and hyperglycaemia with ketosis in the two 
ADJUNCT studies.19–23
Importantly, the effect of short-acting compounds on 
postprandial glucose excursions may be of particular 
interest as several studies have shown a strong correla-
tion between postprandial glucose control and glycated 
haemoglobin (HbA1c) in type 1 diabetes.18 However, no 
large controlled clinical trial evaluating the short-acting 
GLP-1RA treatment effect in type 1 diabetes has been 
reported. Smaller, mainly mechanistic, studies of exen-
atide, a short-acting GLP-1RA normally administered 
two times per day, have shown reductions in postpran-
dial glucose excursions and insulin requirements (0.17–
1.19 U/kg/day) together with weight loss (2.8–4.5 kg) and 
improved, or at least unaltered, glycaemic control.24–26 
The main mechanisms for these effects seem to involve 
deceleration of gastric emptying,27–29 and possibly 
reduced postprandial glucagon secretion.30 31 Impor-
tantly, exenatide given two times per day did not decrease 
the glucagon response during a hypoglycaemic clamp 
after 4 weeks of treatment,32 indicating that exenatide’s 
blood glucose-lowering effects do not compromise the 
main counter-regulatory effects during hypoglycaemia.
Hypothesis
We hypothesise that add-on therapy of exenatide 10 µg 
three times per day at main meals to basal–bolus insulin 
therapy in normal to overweight/obese persons with type 
1 diabetes with inadequate glycaemic control (HbA1c 
between 58 and 86 mmol/mol) will reduce insulin 
requirements, glycaemic excursions and body weight and 
improve glycaemic control without increasing the risk of 
hypoglycaemia.
objectives and endpoints
The overall objective of the present study is to evaluate 
the safety and efficacy of the short-acting GLP-1RA, exen-
atide, administered three times per day (before each main 
meal) as add-on therapy to standard basal–bolus insulin 
regimen in persons with type 1 diabetes. The primary 
endpoint is change in HbA1c after 26 weeks of treatment 
compared with placebo. Secondary endpoints include 
changes in glycaemic excursions; insulin dose; hypogly-
caemic and adverse events; body weight, lean body mass, 
fat mass; dietary patterns; quality of life and treatment 
satisfaction; cardiovascular-disease risk profile; metabolo-
mics; and arginine-tested plasma glucose, glucagon and 
C-peptide levels (box 1).
trial design
The MAG1C trial (Meal-time Administration of Exen-
atide for Glycaemic Control in Type 1 Diabetes Cases: a 
randomised, placebo-controlled trial) is a 26 weekinves-
tigator-initiated, two-armed, parallel group, randomised, 
double-blinded and placebo-controlled study.
MEtHods And AnAlysIs
In total, 100 persons with type 1 diabetes on basal-bolus 
insulin therapy will be randomised in a 1:1 ratio to 
either meal-time exenatide 10 µg three times per day or 
placebo as add-on therapy to regular insulin treatment. 
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A study-independent person will use a computer-gener-
ated randomisation list for treatment allocation. Data will 
be stored in paper-based case report files (CRF). Double 
data entry into a digital database with range checks for 
data values will be used. In case of emergency, unblinding 
will be made on an individual basis not affecting other 
study participants. All data will be pseudoanonymised.
study population
Study participants will be recruited from outpatient 
clinics in the Capital Region of Denmark. All recruited 
participants meeting the eligibility criteria at screening 
will be enrolled in the study and treated for the following 
26 weeks at the Steno Diabetes Center Copenhagen, 
Gentofte, Denmark (box 2).
trial visits and examinations
Study participants will be provided with written and oral 
information by the investigator prior to obtaining written 
informed consent at Steno Diabetes Center Copenhagen. 
At screening (visit 0), information on demography, 
medical history, smoking/drinking status and concom-
itant medication will be obtained. Further, a physical 
assessment will be made including heart rate, blood pres-
sure, body weight, hip:waist ratio and electrocardiography 
together with blood samples and urine tests (box 3). 
Six-day continuous glucose monitoring (CGM), together 
with a 3-day diet recording, will be made before rando-
misation (visit 1), at week 4 (visit 2) and at end of treat-
ment (visit 4). Participants not familiar with carbohydrate 
counting will be offered a standard course before entering 
the study. Blood samples and urine tests will be taken 
during the trial (box 3). An arginine test and a dual-en-
ergy X-ray absorptiometry (DXA) scan will be made at 
randomisation (visit 1) and at end of treatment (visit 4) 
(box 3). Insulin doses will be adjusted by the investigator 
or qualified study personnel during the trial at study visits 
based on seven-point plasma glucose profiles, CGM and 
HbA1c. Blood glucose treatment targets will be based 
on international guidelines,9 that is, preprandial values 
of 4–7 mmol/L and postprandial values <10 mmol/L. 
Following randomisation, changes in insulin types are 
not allowed. The study participants will be asked to fill 
box 1 Primary and secondary endpoints
Primary endpoint
 ► HbA1c
Secondary endpoints
 ► CGM: Glycaemic variability and time spent in hypoglycaemia, 
near normoglycaemia and hyperglycaemia
 ► Insulin dose
 ► Hypoglycaemic events
 ► Body weight
 ► BMI
 ► Body composition (hip:waist ratio)
 ► DXA scan: Lean body mass and fat mass composition
 ► Fasting plasma glucose
 ► Dietary patterns
 ► Arginine test: Pre/poststimulatory levels of glucagon, C-peptide and 
glucose
 ► Cardiovascular disease risk profile: Cholesterol levels, biomarkers, 
blood pressure and heart rate
 ► Quality of life and treatment satisfaction
 ► Adverse events
BMI, body mass index; CGM, continuous glucose monitoring; DXA, dual-energy 
X-ray absorptiometry; HbA1c, glycated haemoglobin.
box 2 Eligibility criteria
Inclusion criteria
 ► Type 1 diabetes according to WHO criteria with duration of ≥1 year
 ► Age ≥18 years
 ► BMI >22.0 kg/m2
 ► HbA1c >7.5% and <10.0% at visit 0 (screening)
 ► Able to count carbohydrates
 ► Able to understand the written patient information and to give in-
formed consent
Exclusion criteria
 ► Insulin pump treatment
 ► Hypoglycaemia unawareness (inability to register low blood glucose)
 ► Diabetic gastroparesis
 ► Compromised kidney function (eGFR <60 mL/min/1.73 m2, dialysis 
or kidney transplantation)
 ► Liver disease with elevated plasma alanine aminotransfer-
ase >three times the upper limit of normal (measured at visit 0 with 
the possibility of one repeat analysis within a week, and the last 
measured value as being conclusive)
 ► History of acute and/or chronic pancreatitis
 ► Subjects with personal or family history of medullary carcinoma or 
MEN syndrome
 ► Inflammatory bowel disease
 ► Cancer, unless in complete remission for >5 years
 ► Proliferative retinopathy
 ► Other concomitant disease or treatment that according to the in-
vestigator's assessment makes the patient unsuitable for study 
participation
 ► Alcohol/drug abuse
 ► Fertile women not using chemical (tablet/pill, depot injection of 
progesterone, subdermal gestagen implantation, hormonal vag-
inal ring or transdermal hormonal patch) or mechanical (spirals) 
contraceptives
 ► Pregnant or nursing women
 ► Known or suspected hypersensitivity to trial product or related 
products
 ► Receipt of an investigational drug within 30 days prior to visit 0
 ► Simultaneous participation in any other clinical intervention trial
Withdrawal criteria
 ► In case of pregnancy (or desire for pregnancy), female subjects are 
withdrawn
 ► Lack of compliance to any of the important study procedures in the 
discretion of the investigator
 ► Onset of any disorder considered to compromise the safety by par-
ticipating in the study
 ► Unacceptable adverse effects in the discretion of the investigator
 ► Withdrawal on participants request will be accepted at any time 
without further justification
BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, 
glycated haemoglobin; MEN, multiple endocrine neoplasia types 1 and 2.
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out questionnaires on quality of life (The Audit of Diabe-
tes-Dependent Quality of Life) and Diabetes Treatment 
Satisfactory Questionnaire: status (DTSQs) and change 
version (DTSQc).33 34 Information on adverse events, 
current medication, basal–bolus insulin dose, hypo-
glycaemic events and consultation blood pressure and 
heart rate will be recorded at all visits. Body weight and 
hip:waist ratio will be measured as well, except on visit 3. 
Between-visit telephone contacts will be made to ensure 
the study participants’ safety and compliance together 
with evaluation of insulin treatment. Further, the study 
participants will be instructed to contact the study team 
if any insulin-dosing or glucose control problems occur. 
All contacts will be recorded in the CRF (figure 1 and 
table 1). To further attenuate the risk of hypoglycaemia, 
no insulin is taken on the visit 1 study day and plasma 
glucose is measured before administration of the first dose 
box 3 blood samples
Screening and control visits
 ► Blood haemoglobin, leucocytes, thrombocytes, plasma glucose, 
potassium, sodium, creatinine, TSH, cholesterol, triglycerides, ALT, 
AST, amylase, lipase, serum albumin, total serum-ketones, beta-hy-
droxybutyrate and acetoacetate
Biobank
 ► CVD markers: HsCRP, pro-BNP
 ► Bone markers: CTX, P1NP, sclerostin, osteocalcin
 ► Inflammation markers: IL-2, IL-6, TNF-α
 ► Urine albumin:creatinine ratio, hCG
Arginine test
 ► Glucagon, C-peptide, plasma glucose
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTX, 
C-terminal telopeptide of type 1; CVD, cardiovascular disease; hCG, human 
choriongonadotropin; hsCRP, high-sensitivity C reactive protein; IL-2, 
interleukin-2; IL-6, interleukin-6, P1NP, serum type 1 procollagen N-terminal; 
pro-BNP, prohormone brain natriuretic peptide; TNF-α, tumour necrosis factor-
alpha; TSH, thyroid-stimulating hormone.
Figure 1 Flowchart.  
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of investigational product and 30 min following inges-
tion of a standardised meal. Next, telephone contacts 
are made 1 and 2 weeks after randomisation with careful 
instruction on reporting any hypoglycaemic and hyper-
glycaemic events. Finally, the investigational product is 
started at 5 µg and escalated to 10 µg following telephone 
contact 2, if tolerated. All contacts will be recorded in the 
CRF (figure 1 and table 1). Finally to ensure compliance, 
used investigational product cartridges will be collected 
at study visit.
A substudy on the role of the microbial gut flora, 
approved by the Danish regulatory authorities and volun-
tary to participate in, involving the collection of faecal 
specimens at each study visit will also be conducted.
Patient and public involvement
The MAG1C study aims to attenuate intensive insulin 
treatment side effects: hypoglycaemia and weight gain. 
Further, our study drug regimen will, hopefully, make 
it easier to control blood glucose excursions on a daily 
basis. We evaluate study participant treatment satisfac-
tion and quality of life through questionnaires during the 
study period to make sure our results benefit persons with 
type 1 diabetes. Study participants will be informed of our 
results in layman’s terms as well as their individual exen-
atide/placebo assignment by letters following publication. 
Finally, during the study protocol write-up, a colleague of 
ours with type 1 diabetes read and commented on the 
final protocol draft.
Intervention
Name: Byetta (exenatide) or matching placebo.
Pharmaceutical form: exenatide 0.25 mg/mL, 3 mL 
cartridges in a reusable Ypsopen, for subcutaneous injec-
tion. Placebo, 3 mL cartridges in a reusable Ypsopen, for 
subcutaneous injection.
Pharmaceutical dosage: To minimise the side effect 
risk, exenatide dose, or placebo, will be increased from 
initial 5 µg three times per day to full dosage, 10 µg three 
times per day, 2 weeks after randomisation. The injection 
must occur within 1 hour before the main meals. Dose 
increments can be titrated based on the individual study 
participant’s study drug tolerance, to a minimum of 5 µg 
three times per day 3 months after randomisation. If not 
possible at this time, the participant will be withdrawn 
from the study.
Side effects: Common side effects (1%–10%) include 
nausea, vomiting, diarrhoea, hypoglycaemia and head-
ache. Study participants will be carefully instructed to 
avoid dehydration if gastrointestinal side effects occur.
Shipping and packing: All study medication will be 
produced, blinded, packed and delivered by AstraZeneca, 
the producer of Byetta.
sample size
To be able to detect a difference in change in HbA1c 
(primary outcome) between study arms of 6 mmol/mol 
with 80% power, a 5% significance level and a presumed V
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9 mmol/mol SD, 42 persons should be included in each 
study arm (two-sided test). To allow for a 20% dropout 
rate, 100 persons in total will be included in the study: 50 
in each study arm. The sample size calculation is based on 
data from a similar study on the GLP-1RA, liraglutide.21 
Withdrawn study participants will not be replaced.
data analysis
The per-protocol study population includes all partici-
pants who complete the study with a documented, valid 
baseline and end-of-treatment assessment of the primary 
endpoint without any major protocol violations. In case 
of dropout, last observation is carried forward. The inten-
tion-to-treat population includes all randomised persons. 
Primary-endpoint analysis will be based on the per-pro-
tocol population. Absolute differences and adjusted 
mean changes between groups, together with 95% CI, will 
be reported. The efficacy analysis will be carried out with 
a linear mixed-effect model with visit, treatment and their 
interaction as fixed factors and a random intercept on the 
person level. Variables that are normally distributed will 
be presented as mean±SD or SE of the mean. In case of 
non-normal distribution, non-parametric statistics and log 
transformation will be used. A two-tailed p value ≤0.05 will 
be considered statistically significant. Additional analyses 
will be made from the intention-to-treat population to 
assess the validity of the per-protocol population conclu-
sions if loss of follow-up occurs. These calculations will 
include duration in study and reason for discontinuation.
Following completion of last patient last visit, 
unblinding will be made in two steps. During data anal-
ysis, unblinding will be made on group level, that is, 
participants are assigned to groups 1 and 2. After the 
prespecified data analysis is completed, the specific treat-
ment group will be revealed.
EtHICs And dIssEMInAtIon
We expect the present study to generate important 
information about the use of short-acting GLP-1RAs as 
add-on therapy to insulin in persons with type 1 diabetes. 
We expect to be able to answer two questions relevant 
for numerous persons worldwide: Will meal-time exen-
atide 10 µg added three times per day (at each main 
meal) to regular insulin therapy (1) improve postpran-
dial glycaemic excursions and (2) provide improved, 
long-term glycaemic control measured as HbA1c and 
glycaemic variability?
During the study, a physician will follow each partici-
pant with careful evaluation of insulin treatment with 
glycaemic optimisation and study drug safety and efficacy. 
This is expected to lower the adverse event risk. Exen-
atide is approved for the treatment of type 2 diabetes 
by the European Medicines Agency and by the US Food 
and Drug Administration. Prior studies have shown 
limited side effects such as nausea, vomiting, hypogly-
caemia and headache. Nausea and vomiting, generally 
transient, usually occur within 3 weeks after treatment 
initiation. They can be minimised by gradual dose titra-
tion, as planned in this study. The hypoglycaemia risk is 
reduced by insulin dose reduction at study start and by 
instructing participants in careful blood glucose moni-
toring. Few cases of acute pancreatitis have been reported 
in persons with type 2 diabetes using exenatide, but the 
incidence was similar to the type 2 diabetes background 
population. Overall, the risk of side effects in this study is 
expected to be modest. Arginine injection is a well-vali-
dated, safe method to evaluate pancreatic alpha and beta 
cell function, but potentially associated with transient 
mild flushing, nausea and metallic taste. Vein puncture 
may cause a short pain, risk of a small haematoma and a 
minimal risk of puncture site infection. In total, 400 mL 
blood and 80 mL of urine per person will be collected 
throughout the study. At the two DXA scans, participants 
will be exposed to weak X-ray radiation (less than 1 mSv 
in total). For comparison, the background radiation in 
Denmark is about 3 mSv per year. The risk of complica-
tions, or adverse events, is negligible for all other planned 
study procedures.
Data will be processed and merged into one or more 
scientific articles and published in accordance with the 
CONSORT 2010 statement in international, peer-re-
viewed scientific journals and presented at national and 
international scientific meetings. Positive, negative and 
inconclusive results together with statistical method will 
be published as soon as scientifically justifiable. Astra-
Zeneca commented on the study design but will have no 
influence on trial conduction, data analysis, interpreta-
tion or publication. All data are owned by the authors, 
who all have full data access.
study approval
The MAG1C trial is approved with a current, approved 
(15 February 2018) study protocol V.1.6. It is registered 
at  ClinicalTrials. gov (NCT03017352). The study will 
be conducted under the surveillance and guidance of 
the good clinical practice (GCP) unit at Copenhagen 
University Hospital Bispebjerg in accordance with the 
ICH-GCP guidelines and the Helsinki Declaration. The 
study commenced in January 2017 and is expected to be 
reported in 2019. Presently (May 2018), 58 study partici-
pants have been included in the MAG1C study.
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